Revolution Medicines Starts Phase 3 Trial for Pancreatic Cancer Drug
Revolution Medicines has begun treating patients in its Phase 3 RASolute 309 trial for its drug daraxonrasib (RASONQUE™) combined with zoldonrasib. The trial is evaluating the combination as a first-line treatment for metastatic RAS G12D pancreatic cancer.
, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. NASDAQ:RVMD, a global, commercial-stage oncology company focused on discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, said it has begun treating pat…